ProSomnus Inc

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prosomnus, Inc. is a medical technology company, which engages in the business of developing, manufacturing, and marketing precision intraoral medical devices. It focuses on treating and managing patients with obstructive sleep apnea. The company was founded by Leonard Liptak and Sung Kim in 2006 and is headquartered in Pleasanton, CA.

PLEASANTON, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProSomnus Sleep Technologies (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced record revenues for the quarter ended June 30, 2024 as it formally emerges from reorganization on August 5, 2024.

ProSomnus® Sleep Technologies Announces Record Revenues as it Emerges from Reorganization

PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at SLEEP 2024, a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX.

ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society

PLEASANTON, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy, today announced results for the first quarter ended March 31, 2024.

ProSomnus Announces Strong First Quarter 2024 Revenue Growth

PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at the 2024 American Academy of Dental Sleep Medicine Meeting in New Orleans.

ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting

PLEASANTON, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that four independent scientific abstracts accepted for the 2024 AADSM Annual Meeting contain scientific data utilizing ProSomnus precision devices, with one abstract winning the prestigious Clinical Excellence Award, and another featuring over 1,200 patients.

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

News for ProSomnus Inc Stock (OSAP)